Alphatec Spine Announces Fourth Quarter and Full Year 2012 Revenue and Financial Results

Alphatec Holdings, Inc. (ATEC), the parent company of Alphatec Spine, Inc., announced today financial results for the fourth quarter and fiscal year ended December 31, 2012.

"On behalf of the entire global Alphatec Spine team, I am pleased to report a strong fourth quarter and a great finish to 2012," said Les Cross, Chairman and Chief Executive Officer of Alphatec Spine. "Since I became CEO last year, we have made significant changes to the organization through investments in leadership talent, operational process improvements, product licenses and an acquisition, which collectively contributed to our positive fourth quarter result and should provide a strong foundation going forward.

pSivida Corp. Reports Second Quarter Fiscal Year 2013 Results

pSivida Corp. (PSDV)(PVA.AX), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced financial results for its second quarter ended December 31, 2012.

“We are pleased with the progress of our lead development product, an injectable micro-insert for posterior uveitis. We expect to begin Phase III trials early next quarter on schedule,” said Dr. Paul Ashton, President and CEO. “We intend these trials to form the basis for a future NDA submission and are excited about the role this product could play in treating this serious, underserved disease. The investigator-sponsored Phase II clinical study of this micro-insert in this disease has completed enrollment ahead of schedule and has been expanded to allow the treatment of more patients.”

Rochester Medical Reports Fiscal 2013 First Quarter Results

Rochester Medical Corporation (ROCM) today announced operating results for its first quarter ended December 31, 2012.

The Company reported record sales of $17,252,000 for the current quarter compared to $13,973,000 for the first quarter of last year.  The Company also reported net income of $1,012,000 or $.08 per diluted share compared to net loss of ($75,000) or ($.01) per diluted share for the same period last year.

The 23% increase resulted from a 24% increase in Rochester Medical Direct Sales and a 19% increase in Private Label Sales.  The growth percentages were essentially the same on a constant currency basis which assumes current exchange rates for all periods in order to exclude the impact of foreign exchange variations.

Medical Action Industries Reports Third Quarter Fiscal 2013 Results

Medical Action Industries Inc. (MDCI), a leading supplier of medical and surgical disposable products, today reported financial results for the third quarter ended December 31, 2012, including quarterly net sales of $109.4 million and gross profit of $19.1 million (the highest in Company history) or 17.5% of net sales. The Company generated non-GAAP net income (before a goodwill impairment charge and certain professional fees) of $1.6 million⁽¹⁾or $0.10⁽¹⁾ per diluted share and EBITDA, as adjusted, of $6.1 million⁽²⁾. These gross profit, non-GAAP net income and EBITDA, as adjusted results represent significant increases versus the comparable non-GAAP results for the same period of fiscal 2012. On a GAAP basis, the Company reported a net loss of $55.5 million or $3.39 per diluted share, principally related to the impairment of goodwill of $56.8 million, net of income tax benefit, determined in connection with the Company's annual goodwill impairment test as of December 31, 2012.